Peptide Field Book

Reading settings

Choose a comfortable text size and appearance. Your choices are saved on this device.

DSIP

Taken for deeper sleep

Delta sleep-inducing peptide

Match every finding to its exact substance, formulation, route and study population. A related molecule or approved medicine does not validate a catalog vial.

Human / product-specific records
Explore the evidenceWhy people take it
Compare this compoundRead original sources Community reports
WAGGDASGE
Schematic illustration · View structure evidenceWAGGDASGE
Color key
NonpolarAromaticPositive chargeNegative chargePolar Copper ion D-form or non-natural

At a glance

Why people take it. And what backs it up.

  1. Sleep deeper

    Small studies, mixed results

    Most inject it before bed hoping for deeper, more restful sleep, though many users say they feel nothing.

    Sources (4)

  2. Ease withdrawal

    Small uncontrolled studies

    A few use it to ease opioid withdrawal, such as when coming off morphine or Suboxone; FDA judged the evidence insufficient.

    Sources (4)

Evidence briefing

Sources checked

What the sources support.

DSIP is also called emideltide; Deltaran was entered in the Russian medicines register in 2016 as an intranasal product with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. The accessible registry mirror gives a 2016 entry, while FDA’s 2026 search says the emideltide forms it reviewed were not registered in countries searched, so present-day Russian authorization could not be confirmed. In July 2026 PCAC did not recommend emideltide for the 503A list; this is separate from drug approval.

Keep in mind

The historical Deltaran record does not establish a current authorization or evidence for online DSIP vials; route, product and current registration status remain important uncertainties.

Identity and research status reviewRead the original sources

The research. What’s been studied.

  • Early human studies

    Sleep research

    DSIP was proposed to affect sleep, but small older human studies were inconsistent and do not establish treatment of insomnia.

  • Animal & lab studies

    Stress-response research

    Hormone and pain effects have been explored, mainly in experimental research; clinical benefit is not established.

  • Early human studies

    Withdrawal research

    Small studies explored DSIP for withdrawal symptoms. The evidence does not establish a reliable treatment, and current Deltaran authorization could not be verified.

What do these labels mean?
  • Human evidence: approved-drug data or larger human studies, within the populations and uses studied.
  • Early human studies: small, preliminary or limited human studies.
  • Animal & lab studies: animal or laboratory findings that do not establish effects in people.
  • Unverified: a proposed use or claim without verified supporting clinical evidence.
How each claim was reviewed (3)

Reported effects and evidence.

A citation may support, qualify or correct a claim. Read the study scope; a laboratory result is not an established benefit in people. Each review covers a claim as it was first collected; the tiles above show the collection’s current wording.

  1. Small older human trials; inconsistent benefit

    Review of “Deeper sleep”

    Small older DSIP insomnia trials produced inconsistent results and do not establish a reliable deep-sleep benefit.

    Limitations and applicability. The title promises deep sleep, but studies were small and inconsistent; one found no likely major therapeutic benefit.

    Original collected claim and review history

    Original title: Deeper sleep

    Proposed to promote deep, delta-wave sleep; small 1980s studies gave inconsistent results.

    Original label: early. Preserved for traceability; the reviewed wording above qualifies this record.

    Record dsip:benefit:1 · Annotated 2026-10-01 · Review method

  2. Very small human pain pilot; stress-hormone component unresolved

    Review of “Stress hormone balance”

    An early seven-patient pilot reported pain changes. Stress-hormone claims require separate measured endpoints and primary sources.

    Limitations and applicability. Seven-patient uncontrolled pain report is weak evidence; it does not validate the broad phrase “stress hormone balance.”

    Original collected claim and review history

    Original title: Stress hormone balance

    Studied for effects on stress hormones and pain.

    Original label: animal. Preserved for traceability; the reviewed wording above qualifies this record.

    Record dsip:benefit:2 · Annotated 2026-10-01 · Review method

  3. Old uncontrolled clinical withdrawal report

    Review of “Withdrawal symptom relief”

    An old uncontrolled report described withdrawal-symptom changes with substantial missing evaluations; it does not establish modern treatment efficacy.

    Limitations and applicability. 1983 report began with 67 patients and excluded/lost 27%; no controlled comparison. Russian label remains a separate unverified citation.

    Original collected claim and review history

    Original title: Withdrawal symptom relief

    Explored in small studies for alcohol and opioid withdrawal. In Russia it is approved as nose drops (Deltaran) for alcohol dependence and withdrawal, alongside other treatment.

    Original label: early. Preserved for traceability; the reviewed wording above qualifies this record.

    Record dsip:benefit:3 · Annotated 2026-10-01 · Review method

The research in detail

Evidence category

Small or older human studies

Small older human studies of DSIP for sleep reported inconsistent results. It has also been explored for withdrawal-related symptoms, but findings do not establish a reliable treatment. The Deltaran entry dated 2016 was located through a secondary mirror of the Russian register; its current validity was not confirmed, and FDA’s 2026 country search did not identify the emideltide forms it reviewed as registered. The July 2026 advisory committee did not recommend emideltide for the 503A list; that vote is not a drug-approval decision.

Evidence is assessed claim by claim above. Regulatory approval, study design, findings and relevance are separate questions; there is no single evidence score.

Risks and unknowns. What to know first.

Collected cautions follow. These are not an exhaustive or independently validated safety assessment; claim references do not automatically support every caution.

  • Limited data.
  • Reported effects include headache and grogginess.

What people report

Show all 11 cautionsShow fewer cautions

Read this first: what “research use only” means

Published dosing records. What the label abroad says.

Historical label and trial records for the named product, route, population and indication. These records are not a personal schedule or a validated regimen for a catalog vial. Source attribution does not establish applicability.

Deltaran (historical label)

Historical Russian label: adjunctive treatment of alcohol dependence, withdrawal and stress-related conditions. Current authorization was not verified.

Fixed courseLabel abroad

Source: Deltaran instructions for medical use, Russian State Register of Medicines (GRLS), reg. no. ЛП-№(016126)-(РГ-RU), 2026 version

Each dose (one ampoule)
0.3 mg
How
Nose drops: one ampoule dissolved in 0.5 mL of boiled water, into both nostrils
How often
Once a day to start. For the alcohol uses it can go up to 2–3 times a day; for stress-related conditions, 1–3 ampoules a day
How long
5–10 days. The label doesn’t say whether a course can be repeated

Limit. No more than 3 ampoules a day.

  • This historical label concerns Deltaran: an ampoule with DSIP and glycine. Current Russian authorization was not verified in the October 2026 source review. It does not validate research-vial DSIP.
  • Each ampoule is dissolved in 0.5 mL of boiled, room-temperature water just before use, put into both nostrils and used up at once; the solution is not kept.
  • Not for anyone under 18, or in pregnancy or breastfeeding.
  • The historical label described use as part of combined treatment and directed severe alcohol withdrawal to medical care.
  • The label advises against it with a very slow heart rate. Listed side effects are allergic reactions and irritation inside the nose.
  • Deltaran was first registered in Russia in 2016. That older label gave one regimen for every use: 1–3 ampoules a day for 5–10 days.

Insomnia trial

Small double-blind, placebo-controlled trial in 16 people with chronic insomnia (Neuropsychobiology, 1992)

Given by a clinicianClinical trial

Source: Bes et al., Neuropsychobiology, 1992

Days 1–3
25 nmol/kg
How
Into a vein
How often
Once a day, in the afternoon
How long
3 days in the trial
  • Doses were given into a vein during a stay in a sleep laboratory. No dose for injection under the skin has been established.
  • Other small studies used the same 25 nmol per kg dose, for example on four nights (Monti et al., 1987) or once in the morning by slow drip (Schneider-Helmert et al., 1981).
  • Controlled insomnia trials disagree: two independent ones concluded any benefit was small (Monti et al., 1987; Bes et al., 1992), while another double-blind trial reported clear improvement (Schneider-Helmert, 1987).
  • 25 nmol per kg works out to about 21 mcg per kg of body weight (calculated from DSIP’s molecular weight, 848.8).

This schedule comes from the cited national product label. Authorization and availability can change: check the current local status and exact formulation. A research vial is not the labeled product.

These doses were tested in clinical trials under medical supervision. They aren’t approved for use, and a research vial is not the product that was tested.

Community protocols. Reported online. Not clinically validated.

Community reports Collection date: 30 Sep 2026

Most people inject 100–300 mcg under the skin 30 minutes to 3 hours before bed, often only a few nights a week or in short runs of 5–10 nights.

More about this

Practice varies a lot: clinic and book protocols use 100–150 mcg two or three times a week, while many 2025–2026 Reddit users take 500 mcg–1.5 mg and a few take 2–3 mg.

Not testedFrequently encountered in reviewed sources

Bedtime injection, 100–300 mcg

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
100–300 mcg (250 mcg is the single most quoted figure)
How often
Once a night, but many use it only some nights (for example 5 nights on and 2 off, or every other night)
Route
Injection under the skin
Timing
30 minutes to 3 hours before bed; most say about 1 hour
How long
Short runs of 5–10 nights are common on Reddit; Jay Campbell’s plan runs 8 weeks
Cycle
Jay Campbell: 5 days on, 2 days off for 8 weeks, then 8 weeks off. Reddit users often run 7–10 nights, then take 3–4 weeks off.
Ramp
Many start at 100–150 mcg and add about 50 mcg every few nights until sleep feels deeper
Mixing
2 mg vial + 2 mL bacteriostatic water (1,000 mcg per mL, so 250 mcg is 0.25 mL); people with 5–10 mg vials add 2–3 mL
  • Users say it deepens sleep more than it helps them fall asleep.
  • Several report next-morning grogginess above about 250–500 mcg and go back down.
  • Jay Campbell himself says this under-the-skin protocol has not been tested; the human studies gave DSIP into a vein.
  • FDA’s 2026 review found US wellness clinics, medical spas, neurology clinics and online sellers marketing DSIP injections and nasal sprays, including a ready-to-use kit at 2 mg per mL.
Sources (4)

Not testedCommon

Low dose two or three nights a week (pharmacy and book protocol)

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
100–150 mcg
How often
2–3 nights a week (Dr. Seeds also allows daily, every 3 days or once a week)
Route
Injection under the skin
Timing
1–3 hours before bed (Seeds: about 3 hours; Greenfield: 1 hour)
How long
Ongoing; no fixed length given
Cycle
No off period stated by the pharmacy; users who favor this say nightly use makes it stop working
Ramp
Some take it nightly for the first week, then drop to twice a week
Mixing
Pharmacy product: 1,000 mcg per mL in a 3 mL vial, so 0.1 mL = 100 mcg
  • This is the Tailor Made Compounding (Kentucky) protocol from its 2019 catalog; the pharmacy compounded DSIP from 2018 to 2020 and US clinics used it.
  • Dr. William Seeds’ book Peptide Protocols (2020) and Ben Greenfield’s book Boundless give the same low range; Greenfield says he uses it sparingly because the response fades with repeated doses.
  • Reddit users who prefer this range say a higher dose or daily use ‘takes the effect away’.
Sources (4)
Show all 6 protocolsShow fewer protocols

Not testedCommon

Higher nightly dose, about 350 mcg–1.5 mg

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
About 350 mcg–1.5 mg (often 500 mcg–1 mg)
How often
Once a night, or every other night
Route
Injection under the skin
Timing
About 1–3 hours before bed
How long
From a few nights to months; one user reports over a year
Cycle
Some take weekends off; others stop for a few days when it seems to wear off after 4–5 nights
Ramp
Typical pattern: start at 200–300 mcg and raise it every night or two until an effect appears (for example 300 mcg, then 600 mcg, then 1 mg)
Mixing
5–10 mg vials with 2–3 mL bacteriostatic water
  • Mostly from 2025–2026 Reddit threads, where these users say 100–300 mcg did nothing for them.
  • Other users in the same threads report grogginess or no benefit at these doses.
Sources (4)

Not testedSometimes seen

Microdose, 50–100 mcg

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
50–100 mcg
How often
Once a week at first, building up (Jay Campbell’s older page); others a few nights a week
Route
Injection under the skin
Timing
1–3 hours before bed (one user takes 100 mcg at about 9 am and says it helps that night)
Ramp
Jay Campbell: start at 50 mcg once a week, then slowly raise the dose and how often
  • People who favor low doses describe a ‘U-shaped’ response, where taking more works less well; this is also suggested after vivid dreams or wakefulness at higher doses.
Sources (4)

Not testedFringe

Very high dose, 1–3 mg (including a ‘trial dose by body weight’ plan)

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
About 21 mcg per kg of body weight (roughly 1–2 mg) in the weight-based plan; other users report 2–3.3 mg
How often
Once a night for 1–4 nights (weight-based plan); others Monday to Friday, 3 times a week, or every other night
Route
Injection under the skin
Timing
Shortly before sleep
How long
1–4 nights, repeated now and then (weight-based plan); others run it for weeks
Cycle
Short courses, then stop (weight-based plan); weekends off (others)
  • The weight-based plan, posted on the Peptide Critic forum, copies the dose that 1980s studies gave slowly into a vein (25 nmol per kg) and gives it as a shot under the skin instead.
  • Forum users on 1–2 mg reported hangover feelings and headaches and dropped to 0.5 mg; several others felt nothing even at 2–2.5 mg.
Sources (4)

Not testedFringe

Nasal spray

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
About 45–250 mcg (or a few sprays of unstated strength)
How often
Nightly, or about twice a week
Route
Nasal spray
Timing
Before bed
Mixing
Homemade: for example 5 mg in about 10 mL water (one user added a little DMSO, a solvent); most prefer saline over bacteriostatic water, which can sting
  • Some mix DSIP into one spray with Selank or epitalon.
  • A ready-made spray called ‘Dream Catcher’ (with GABA and melatonin) is mentioned; another user stopped it because of nasal irritation.
  • One user had nightmares with the nasal form and switched to injections; others think injections work better.
Sources (4)

Where the numbers come from

Human studies in the 1980s gave DSIP slowly into a vein at about 25 nmol per kg (about 21 mcg per kg, roughly 1.5–2 mg for an adult). The popular under-the-skin doses of 100–250 mcg do not come from any trial. They trace to US clinic practice (the Tailor Made Compounding pharmacy’s 100 mcg two or three times a week, around 2018–2020), Dr. William Seeds’ Peptide Protocols book (100 mcg) and Ben Greenfield’s Boundless (150 mcg three times a week), and were spread further by Jay Campbell’s 250 mcg ‘cheat sheet’ protocol. Since 2025 many Reddit users report higher doses (350 mcg–1.5 mg), and one forum protocol copies the full trial dose by body weight as a shot under the skin.

Home-made sprays and serums

Home-made nasal spray. Community recipes. Not tested.

Original source recordsHide

DSIP is used as a nasal spray, mostly bought ready-made from vendors or compounding pharmacies; a few users make their own by diluting a 5 mg vial in saline, one with a detailed 50 mcg-per-spray method. Evidence is community-level; one small human study used intranasal DSIP.

Best evidence: One human study of intranasal DSIP (Hruz et al., J Clin Psychopharmacol 2001, P300 brain-wave measure). Otherwise community only; one user’s compounding pharmacy shipped them DSIP nasal spray (2025), and vendors sell ready-made sprays (e.g. 5 mg in 5 mL; 5 mg in 10 mL; 4 mg in 30 mL).

Collected strength records

Not testedNasal sprayCommon

Ready-made vendor DSIP sprays (for comparison)

Original source-specific report. Collection checked 30 Sep 2026; presentation annotated 2026-10-01. Source date and reporter identity are not separately verified. Exact form and route are limited to the source’s description.

Batch: 5–30 mL

Ingredients and methodHide the recipe

Ingredients

IngredientAmountRole
DSIP5 mg in 5 mL; 5 mg in 10 mL; or 4 mg in 30 mL (different vendors)Active
How it’s used
Users report 1 spray per nostril about 1 hour before bed, or 200–400 mcg.
Per dose
Often not on the label (one user: ‘the label doesn’t specify how much DSIP is in each spray’).
  • Limitless Biotech lists DSIP spray in a ‘5mL amber glass bottle with spray pump’.
  • One user says they use DSIP ‘in a nasal spray with gaba’ (no amounts).
Sources (7)

Not testedNasal spraySometimes seen

5 mg vial as a concentrate, 2.2 mg diluted to 2 mL with saline spray: 50 mcg per spray

Original source-specific report. Collection checked 30 Sep 2026; presentation annotated 2026-10-01. Source date and reporter identity are not separately verified. Exact form and route are limited to the source’s description.

Batch: 2 mL

Ingredients and methodHide the recipe

Ingredients

IngredientAmountRole
DSIP2.2 mg (0.22 mL of a 5 mg in 0.5 mL concentrate)Active
Bacteriostatic water (to make the concentrate)0.5 mL per 5 mgLiquid
Saline nasal spray1.78 mLLiquid

Method

  1. Fill the empty sprayer with 2 mL of liquid, prime it, and count how many sprays 2 mL gives (this bottle: 22 sprays per mL).
  2. Dissolve 5 mg DSIP in 0.5 mL bacteriostatic water (10 mg per mL concentrate).
  3. Draw 0.22 mL (22 insulin-syringe units) = 2.2 mg into the bottle and add 1.78 mL saline nasal spray (2 mL total).
  4. Keep the rest of the concentrate for later bottles.
How it’s used
2 sprays per dose (100 mcg); 44 sprays = 22 doses.
Per dose
About 50 mcg per spray (stated as 100 mcg per 2 sprays).
Preservative
Only the small amount of bacteriostatic water in the concentrate.
  • The same user made an epitalon spray for their father the same way.
  • The poster said bacteriostatic water bothers some people, who use sterile water instead.
Sources (4)

Not testedNasal sprayFringe

5 mg in 1 mL saline (disputed)

Original source-specific report. Collection checked 30 Sep 2026; presentation annotated 2026-10-01. Source date and reporter identity are not separately verified. Exact form and route are limited to the source’s description.

Batch: 1 mL

Ingredients and methodHide the recipe

Ingredients

IngredientAmountRole
DSIP5 mgActive
Saline1 mLLiquid
Preservative
None (‘no alcohol’).
Storage
Fridge; use it up as quickly as possible.
  • Another reply called this ‘way off’ and said a UK vendor’s 30 mL DSIP spray contains 4 mg.

Not stated: how it’s used and the amount per dose.

Sources (3)

Not testedOtherFringe

Intranasal DSIP in a human study (reference, not a home recipe)

Original source-specific report. Collection checked 30 Sep 2026; presentation annotated 2026-10-01. Source date and reporter identity are not separately verified. Exact form and route are limited to the source’s description.

Ingredients and methodHide the recipe

Ingredients

IngredientAmountRole
DSIPdose not available in the abstract recordActive
How it’s used
Not available.
  • Published as a short letter; no abstract or formulation details were available.
Sources (1)

How the method was put together, step by step with its sources

Editorial synthesis and reported strength comparison

This synthesized method combines source records. It has not been validated for preparation, sterility, compatibility, absorption or storage. Select a reported strength to inspect the arithmetic; no strength is selected for you.

Strength
What people report
Research notes

Dose conversion error in a popular source: Jay Campbell’s DSIP chart page says the trial dose (25 nmol per kg) works out to about 190–210 mcg for a 90 kg man, but by DSIP’s molecular weight (about 849) it is about 1.9 mg, and the FDA briefing gives 25 nmol/kg as 21.3 mcg per kg. So the common 100–300 mcg shot is roughly one-tenth of the trial dose, and the trials used a vein, not the skin. Sources disagree sharply on dose: some say less works better (50–200 mcg) and more causes grogginess or stops working; others only respond at 375 mcg–1.5 mg, and some take 2–3.3 mg. Paradoxical wakefulness is reported. Nasal use is rare and poorly described. MESO-Rx (login wall) and Professional Muscle (bot check) threads could not be opened, so they are not included.

Nasal spray

Recipes disagree widely: ‘1 mL saline for every 5 mg’ versus a vendor’s ‘4 mg in 30 mL’. Vendor bottles often don’t state mcg per spray. One user adds GABA to a DSIP nasal spray (no amounts). The 2001 human study is a short letter; its dose was not available in this search.

Measurement basics and calculator

Explore vial arithmetic

What it is. In plain English.

DSIP (emideltide) has small, inconsistent human studies and a historical Russian Deltaran registry entry; current authorization could not be confirmed.

Isolated in 1977 from the blood of rabbits put into deep sleep. No gene for it has ever been found in humans.

Its mechanism is unclear. It was proposed to promote deep (delta-wave) sleep and to modulate stress hormones and pain.

Reviewed 2026-10-01.

Structure. Nothing to show yet.

No experimental 3D structure of delta sleep-inducing peptide (DSIP) is in the .

The name matches are unrelated proteins and a screening library called DSiP, and its 9-amino-acid sequence occurs in no chain of any entry.

Checked 30 Sep 2026.

Specs. The facts at a glance.

Length
9 amino acids
Sequence
WAGGDASGE
Sold as
  • DSIP 10 mg
Regulatory status
A secondary mirror of the Russian State Register shows a Deltaran/emideltide entry dated 2016; current authorization is unverified. Not FDA-approved. In July 2026 the advisory committee did not recommend emideltide for possible 503A bulk-list inclusion; this is separate from drug approval.
Also known as
Delta sleep-inducing peptide

Sources. What this page rests on.

Every source behind this page, with what it says and when it was checked, is in the Source library.

DSIP in the Source library

Original overview and research notes · annotated 2026-10-01

Historical collection text. Read alongside the claim corrections above; identity or evidence qualifications may supersede this wording.

Sleep support (unconfirmed)

A “sleep-inducing” peptide from 1970s rabbit research whose effects have been hard to confirm.

Isolated in 1977 from the blood of rabbits put into deep sleep. No gene for it has ever been found in humans.

Its mechanism is unclear. It was proposed to promote deep (delta-wave) sleep and to modulate stress hormones and pain.

Small human studies in the 1980s gave inconsistent results for insomnia; a few explored it for withdrawal symptoms, and interest in the West faded because the effects didn’t reliably replicate. Russia registered it in 2016 as Deltaran, nose drops used alongside other treatment for alcohol dependence and withdrawal and for stress-related conditions.

Original status record: Approved in Russia since 2016 as Deltaran, nose drops for alcohol dependence and withdrawal and for stress-related conditions; not approved in the US or EU. In July 2026 an FDA advisory panel voted against letting pharmacies compound it.

More in Brain, mood & sleep.

Glossary

Protein Data Bank (PDB)

The free worldwide archive of 3D structures of proteins and other molecules measured in experiments. Each entry has a four-character code, like 7KI0.

Full glossary